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ABSTRACT 
 
Background- Hypertension is a common occurance in our society. Microalbuminuria  is already evaluated in 
hypertension as  a marker of cardiovascular risk and target organ damage. Ischemia modified albumin is a novel 
marker of oxidative stress.  Materials and methods-84 hypertensive patients (36 without microalbuminuria and 48 
with microalbuminuria) were selected for the study. 29 age and sex matched control subjects were also selected 
.Ischemia modified albumin was assayed in all the study subjects by albumin cobalt binding assayin 
semiautoanalyser. Urinary albumin creatinine ratio was also measured in all study subjects. Statistical analysis was 
done in graphpad software & statistical calculator software. Results: ANOVA showed Significant increase of 
ischemia modified albumin (p<0.005) and microalbuminuria (p<0.0001) between three groups. Furthermore student 
t test showed the significant increase of ischemia modified albumin in hypertensives without microalbuminuria 
(p<0.05) than controls. Conclusion- Ischemia modified albumin assay is a simple, rapid and cost effective test, can 
predict the microalbuminuria and can aware the future complications of hypertension in sufficient early stage. 
 
Keywords: Conjunctival autograft, Primary pterygium, Recurrent pterygium 
Introduction 
 
 
Hypertension is a common public health problem 
currently and affects all the socioeconomic classes. 
Essential hypertension, often asymptomatic and silent 
killer, till at diagnosis it can present with ischemic 
heart disease(IHD), stroke, myocardial infarction(MI), 
and other vascular disorders[1]. By thr year 
2025,29.2% of the population are expected to have 
hypertension. Approximately 54% of all strokes and 
47% of IHD were contributed to high blood pressure 
[2]. Hypertension was reported as 4th contributor of 
premature death in developed countries and 7th in 
developing countries [3].  
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In Indian Scinario, it affects 5.99% and 6.99% in males 
and females in urban population[1]. Ischemia modified 
albumin (IMA) is a recent biomarker used for the 
diagnosis of acute coronary syndrome [4].  IMA was 
first described as a marker of myocardial ischemia, but 
lately it is being intensively investigated in other 
disorders, including diabetes, and in other conditions 
associated with oxidative stress [5,6]. IMA was also 
studied in hypoxic conditions like preeclampsia [7] or 
birth asphyxia[8]. Using the advanced techniques it has 
been observed that N-terminus of albumin is 
particularly susceptible for degeneration by ischemia 
cord ima [1] Roy et al has suggested that reactive 
oxygen specis (ROS) can modify the N terminus of 
albumin which can result in decreased affinity to 
cobalt. The resulting molecule, IMA and its reduced 
binding to cobalt can be utilized by the albumin cobalt 
binding assay (ACB) [9] IMA has been studied in 
hypertension. Kumar A et al found that the IMA has 
increased significantly in hypertensives than 
normotensives. They also indicated the prognostic 
value IMA in hypertensives [10].Non diabetic 
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microalbuminuria, was already considered 
under evaluation of essential hypertension
Microalbuminuria has also considered as an integrate
marker of cardiovascular risk
Microalbuminuria has been also studied in essential 
hypertension and target organ damage [13,14]. 
albumin levels also predict cardiovascular morbidity 
and mortality[15]. Urine albumin concentrations 
measured in 'spot' morning collections are frequently 
standardised for concurrent creatinine excretion to 
derive albumin creatinine ratios( ACRs). This 
procedure corrects for unknown urine volumes but 
needs differentiation of males from females in whom 
creatininuria is lower because of reduced muscle mass, 
a fact not always taken into account [16,17]. In 
addition, creatinine excretion in the urine depends not 
only on gender but also on age and race [18,
19].Systemic BP may exert some modulating influence 
on albuminuria even in normoalbuminuric hypertensive 
patients[20]. An interesting and emerging issue is high 
normal albuminuria (somewhere between 8
or 15-30 mg/24 h) as a condition of increased 
cardiovascular risk [11].From the above facts we 
observed that IMA and microalbuminuria in the form 
of albumin creatinine ratio have proven their own 
efficiencies as a prognostic marker of hypertension. A 
very few studies have conducted to observe the 
association between gradual increase of oxidative 
stress and development of complications of 
hypertension. Considering all these facts, we tried to 
asses a reliable and early marker, which can guide us to 
predict the severity and complications of hypertension.
 
Materials and methods 
 
 Study design 
Cross sectional hospital based study 
Study site 
The study was carried out at the Department of 
Biochemistry, Calcutta National Medical College and 
Hospital (CNMCH) 
 Duration of study 
The duration of study was six months (01.10.2013
31.03.2014)  
Selection of cases and controls 
A total of 84 hypertensive patients (36 with normal 
UACR and 48 of increased ACR (49 males and 35 
females), aged 40 to 60 years) were selected. Informed 
consent was taken from them. Cases were selected 
from clinically newly diagnosed hypertensive patients 
attending the medicine outdoor patient department of 
Calcutta National Medical College. 29 (19 male and 10 
female) age and sex matched healthy control subjects 
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without any family history of hypertension were also 
selected for the study, with consent.
 Inclusion criteria: Subjects between the age group of 
40 -60 years were selected. Samples from cases were 
collected before institution of any antihypertensive 
treatment. The criteria for diagnosis of hypertension 
were systolic pressure of >140 mm of Hg and diastolic 
pressure of >90 mm of Hg.  
 
Exclusion criteria 
 
Hypertensive patients who were already on anti
hypertensive treatment were excluded from the study. 
Study subjects were examined systematically to 
exclude any disease (Secondary hypertension) or 
factors known to cause or associated with 
hypertension. Subjects on drugs like steroids, oral 
contraceptive pills, and thyroxin were excluded from 
the study. Patients with diabetes mellitus, renal 
insufficiency, hepatic disease or taking lipid lowering 
drugs or antioxidant vitamin supplements were 
excluded. 
 
Ethical Clearance 
 
Before commencement of the work, Ethical Clearance 
was obtained from the Institutional Ethics C
according to the Helsinki Declaration. Written 
informed consent was taken from cases and control 
subjects.  
 
Methods for analysis of test parameters Blood 
pressure measurement 
 
Blood Pressure of the study subjects were measured in 
sitting posture. The instrument used was mercury 
sphygmomanometer (cuff size 12.5x40 cms).Systolic 
and diastolic blood pressures were taken according to 
the criteria. Two readings were recorded from them 
with a difference of 5 minutes 
Organization guidelines.[21].
(≥140/90 mmHg) was noted, a third reading was taken 
after 30 min. The lowest of the three readings was 
taken as blood pressure. Thus the patients were 
diagnosed as hypertensive. 
Sample collection: Blood 
5 ml of venous blood is collected and serum was 
separated. Estimation of IMA was done immediately.
Urine: First morning samples of urine from the same 
patients were taken. 
ACB Assay for IMA 
Principle 
ACB assay for determination of the level of IMA in 
serum is done by addition of a known amount of cobalt 
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(II) to a serum specimen and measurement of the 
unbound cobalt (II) from the absorbance of the colored 
complex between dithiotreitol (DTT) and free cobalt by 
spectrophotometer which is indicative of the level of 
IMA [22]. Intensity of the colored complex varies 
inversely with the ACB. 
Assay protocol 
A volume of 200 µL of serum was mixed with 50 µL of 
1 g/l cobalt chloride (CoCl2) solution. Vigorous 
mixing was done followed by incubation for 10 min. 
Then 50 µL of 1.5 g/l solution of DTT was added and 
mixed following which an incubation for 2 min. 
Finally, 1 ml of 9 g/l of NaCl was added, and 
absorbance was read at 470 nm in a spectrophotometer 
[23]. The blank was prepared similarly with the 
exclusion of DTT. Standard curve was prepared using 
different concentrations of CoCl2 and values of IMA 
were expressed in units/ml. 
Urine concentrations of creatinine were determined 
using the method described by Jaffe [24]. The 
concentration of albumin in urine was determined 
according colorimetric method described by Shosinsky 
et al. based on the ability of albumin to bind to 
bromophenol blue (BPB)[25] The results vary linearly 
with range of albumin concentration up to 6 g/l. The 
intra-assay and inter-assay CV was 3.2% and 6.5%, 
respectively. On this basis, we calculated the urinary 
albumin/creatinine ratio and divided individuals into 
groups with normal albuminuria (UACR <30 mg/g), 
and microalbuminuria (UACR 30-300 mg/g). 
 
Statistical analysis 
Done by using graphpad software & statistical 
calculator software  
 
RESULTS   
 
 ANOVA showed there was a significant difference in 
mean serum IMA levels between 3 groups (Table 1). 
As revealed by student t test, difference among  group 
1 (Controls) and group 2 (Hypertensives with normal 
ACR) was significant, but  among group 2 and group 
3( Hypertensives with increased ACR) was not 
significant (Table 2). 
Table 1:  ANNOVA shows IMA & UACR between three groups 
 
 Normotensive 
(n=29) 
Hyertensive with 
normal UACR 
(n=36) 
Hypertensive 
with increased 
UACR 
(n=48) 
F Value p-value 
IMA(Units/ml) 95.93±30.43 115.25±18.15 125.27±29.48 5.571 <0.005 
UACR(mg/g) 22.19± 1.99 20.50±7.25 218.36± 50.23 489.494 <0.000 
 
Table 2 : Student`s t-test shows significant difference of IMA  between 2 groups 
Group p 
IMA level of  control  & hypertensive groups with 
Normal UACR 
0.0023 
IMA level of  hypertensive groups with normal 
UACR & increased UACR 
 
0.0758 
 
Discussion 
 
Hypertension is widely established as a potential risk   
factor for atherosclerosis and cardiovascular disease   
which is the leading cause of morbidity and mortality  in 
all developed and developing countries in the world  
including India[26]. Increased oxidative stress is one of 
the principal mechanisms by which it may exert its 
pathological influence[27].According to Piwowar A, IMA 
may be a good clinical marker  with higher specificity to 
reveal individuals with upper normal albuminuria. 
Diagnostic usefulness of IMA in estimating kidney 
dysfunction is the ability to distinguish individuals 
without any kidney disturbance ( normoalbuminuria) from 
those with kidney disturbance (micro or upper normal 
albuminuria)[28].The levels of IMA was found to increase 
progressively with the degree of albuminuria in patients 
with diabetes. A significant positive correlation 
coefficient was also observed between UACR and plasma 
IMA levels in them.[29].Ischemic hypoxia modifies 
albumin at N-terminus residues reducing its affinity to 
Cobalt [30,31]. Chief factor involved in modifying the 
metal binding domains of albumin molecule is the 
generation of reactive oxygen species due to ischemia 
reperfusion injury. Plasma IMA levels are reported to 
correlate with parameters of oxidative stress like advanced 
oxidation protein products and thiol groups [32]. 
Microalbuminuria is a predictor of cardiovascular 
events[33]. Hillege et al[34] stated that urinary albumin is 
a  risk marker with, while Klausen et al [35] showed that 
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only slightly raised level of albumin well in the 
normoalbuminuric range is  related to increased 
cardiovascular risk.A lot of studies reviewed  the 
association of microalbuminuria and cardiovascular 
risk.[36,37]. Above studies mentioned that 
microalbuminuria was clustered with other cardiovascular 
risk factors like age, diabetes, hypertension, left 
ventricular hypertrophy ,obesity, metabolic syndrome etc. 
Careful screening of those factors and post hoc selection 
of healthy individuals in large population  still revealed 
the marked and overwhelming independent predictive 
power of microalbuminuria. It was further supported by 
recent Framingham publication that microalbuminuria 
remains a strong predictor of cardiovascular event even in 
normotensive, non diabetic and normal renal function 
individual.  Microalbuminuria or proteinuria occurs as a 
consequence of renal damage. Physiologically the 
glomerular filter forms a barrier to prevent albumin to 
pass into kidney tubules. Furthermore, proximal tubule is 
equipped with an effective albumin reabsorption system 
that metabolizes albumin to fragments and amino acids. 
Damage to glomerular barrier or proximal tubule can lead 
to increased excretion of albumin or its fragments. 
Moreover an increased tubular burden of albumin 
reabsorption may damage the proximal tubule leading to 
interstitial inflammation and loss of functioning kidney 
tissue [38]Subsequently urinary albumin is increasing 
showing transition from normo to microalbuminuria.Urine 
microalbumin excretion may be associated with 
susceptibility to subsequent organ damage 
[39].Hypertension  brings  about increased oxidative 
stress, hypoxia and endothelial dysfunction leading to 
renal damage[29]. UAE testing improves the accuracy of 
cardiovascular risk assessment in patients with 
hypertension [40,41].We observed that normoalbuminuric  
hypertensive  patients are having increased oxidative 
stress reflected by increased IMA level (Table-1).But 
microalbuminuric hypertensive patients  have shown 
further increase of IMA. Our study has suggested that 
gradual increase of oxidative stress causes further damage 
of renal filtration barrier and proximal tubular cells. 
Increased oxidative stress causes transition from normo to 
microalbuminuric stage in uncontrolled hypertensive 
patients. Our study indicated that IMA levels in 
hypertensive patients predicts microalbuminuria ,so 
intensive effort to control oxidative stress in this level can 
prevent microalbuminuria. This findings are similar to the 
findings of Kumar A [10].The correlation between 
microalbuminuria and mortality was obvious [42]. All-
cause mortality was 9.4% among patients without 
microalbuminuria versus 18.2% among those with 
microalbuminuria. The risk for all-cause mortality in 
patients with microalbuminuria was also elevated , 
especially among those with concomitant 
hypertension[43]. Microalbuminuria independently 
predicted future stroke when compared to patients with 
normoalbuminuria[44]. The presence of microalbuminuria 
during the first week of hospitalization for acute 
myocardial infarction is a strong prognostic marker for in-
hospital mortality, particularly among patients with 
hypertension, and of long-term recurrent coronary events 
or mortality [45]   More recent observation was that, high 
normal albuminuria (somewhere between 15 and 30 mg/d) 
is associated with hyperfiltration which anticipated a 
decline in renal function [46]. IMA can be used with 
higher specificity to reveal individuals with upper normal 
albuminuria [31].So prevention before the development of 
microalbuminuria in hypertension patients can keep the 
patient more safe.It is known that IMA levels rise within 
mintes after ischemia and return to baseline within 4 to 6 
hr [47]. The study conducted by Sameer S et al 
documented that IMA is an early marker of ischemia, 
increases before any detectable change in cardiac 
troponins, and is elevated even in the absence of 
myocardial necrosis. This is especially useful to rule out 
ischemia in the emergency setting, thereby making IMA a 
potentially useful biomarker [48]. 
  
Conclusion 
 
The results of our study have clearly suggested that the 
IMA level in hypertension indicates the status of oxidative 
stress. Furthermore it may be helpful in assessing 
oxidative stress during the  development of kidney 
dysfunction. From the above findings, we can assume 
that, IMA can be incorporated as a diagnostic test 
parameter in hypertensives to avoid the future acute 
coronary complications.IMA test holds promises as it is 
simple, rapid and cost-effective. Furthermore it appears 
before microalbuminuria. IMA result  may help in moving 
the patients into a low risk category by  initial evaluation 
based on the clinical presentation.  
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